SCHEMBL7057299

SCHEMBL7057299

COc1cc2sc(-c3ccccc3)nc2cc1C=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.50
KDM4E B2RXH2 6/20 0.50
NFKB1 P19838 3/20 0.50
NFKB2 Q00653 3/20 0.50
RELA Q04206 3/20 0.50
LMNA P02545 1/20 0.50
HPGD P15428 4/20 0.49
MAPT P10636 4/20 0.49
PKM P14618 3/20 0.49
ALDH1A1 P00352 3/20 0.49
MEN1 O00255 2/20 0.49
GLA P06280 2/20 0.49
GAA P10253 2/20 0.49
KMT2A Q03164 2/20 0.49
RAB9A P51151 4/20 0.48
NPC1 O15118 3/20 0.48
ILK Q13418 1/20 0.46
PPARG P37231 1/20 0.45
NCOA2 Q15596 1/20 0.45
NCOA1 Q15788 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11239816 0.81 SMN1; SMN2 (0.50) SMN1; SMN2KDM4ENFKB1NFKB2RELA
SCHEMBL9435301 0.79 KDM4E (0.57) SMN1; SMN2KDM4ENFKB1NFKB2RELA
SCHEMBL7053654 0.78 SMN1; SMN2 (0.56) SMN1; SMN2KDM4ENFKB1NFKB2RELA
SCHEMBL7053598 0.77 ALOX15 (0.54) SMN1; SMN2KDM4ELMNAHPGDMAPT
SCHEMBL29023858 0.77 KDM4E (0.54) SMN1; SMN2KDM4ENFKB1NFKB2RELA
SCHEMBL7054374 0.76 SMN1; SMN2 (0.51) SMN1; SMN2KDM4ENFKB1NFKB2RELA
SCHEMBL22431 0.75 MAPT (0.73) SMN1; SMN2KDM4ENFKB1NFKB2RELA
SCHEMBL12967447 0.75 KDM4E (0.61) SMN1; SMN2KDM4ENFKB1NFKB2RELA
SCHEMBL2138572 0.75 APP (0.74) SMN1; SMN2KDM4ENFKB1NFKB2RELA
SCHEMBL3187010 0.74 KDM4E (0.68) SMN1; SMN2KDM4ENFKB1NFKB2RELA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030162766-A1 Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists PFIZER INC. 2003-08-28 US claimed
US-20010023248-A1 Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists HOWARD HARRY R (US) 2001-09-20 US claimed
EP-0806423-A1 Aminomethylene substituted non-aromatic heterocycles and use as substance p antagonists PFIZER INC. (US) 1997-11-12 EP claimed
EP-0675886-A1 AMINOMETHYLENE SUBSTITUTED NON-AROMATIC HETEROCYCLES AND USE AS SUBSTANCE P ANTAGONISTS PFIZER INC. (US) 1995-10-11 EP claimed
WO-1994013663-A1 AMINOMETHYLENE SUBSTITUTED NON-AROMATIC HETEROCYCLES AND USE AS SUBSTANCE P ANTAGONISTS PFIZER INC. (US) 1994-06-23 WO claimed
US-20030162766-A1 Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists PFIZER INC. 2003-08-28 US disclosed
US-6369074-B1 Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists PFIZER INC. 2002-04-09 US disclosed
US-20010023248-A1 Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists HOWARD HARRY R (US) 2001-09-20 US disclosed
US-5854262-A Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists PFIZER INC. (US) 1998-12-29 US disclosed
EP-0806423-A1 Aminomethylene substituted non-aromatic heterocycles and use as substance p antagonists PFIZER INC. (US) 1997-11-12 EP disclosed
EP-0675886-A1 AMINOMETHYLENE SUBSTITUTED NON-AROMATIC HETEROCYCLES AND USE AS SUBSTANCE P ANTAGONISTS PFIZER INC. (US) 1995-10-11 EP disclosed
WO-1994013663-A1 AMINOMETHYLENE SUBSTITUTED NON-AROMATIC HETEROCYCLES AND USE AS SUBSTANCE P ANTAGONISTS PFIZER INC. (US) 1994-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010023248-A1 Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists NPY1R, OPRK1, OPRL1 SMN1; SMN2 1543/4885KDM4E 1271/4885NFKB1 1042/4885
US-20030162766-A1 Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists NPY1R, OPRK1, TACR1 SMN1; SMN2 1485/4885KDM4E 1245/4885NFKB1 1258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.